1. Medtech Insight

Argo Preps 510(k) Application For ReWalk Exoskeleton For Home Use

The firm launched the CE-marked, first-of-its-kind device for personal home use in Europe in early September at the International Spinal Cord Society meeting in London.

Argo Medical Technologies is preparing to submit a 510(k) application to FDA in the near future for home use of its ReWalk exoskeleton system, intended to enable people with lower-limb disabilities, such as paraplegia, to stand and walk independently. The firm hopes to gain U.S. market go-ahead in the first half of 2013.

Designed as an alternative to wheelchairs to provide mobility and aid performance of routine activities, ReWalk “is a cutting-edge device that will revolutionize the mobility industry, and we are committed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Execs On The Move: 5-9 May 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.